Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exosomes for Non-Traumatic Avascular Necrosis of the Femoral Head
NCT07787923Phase 1Not yet recruiting
- Sponsor
- Beijing Jishuitan Hospital
- Start
- Sep 2026
- Primary completion
- May 2028
01
Overview
Phase 1, open-label trial of mesenchymal stem cell exosomes in osteonecrosis of the femoral head (ONFH) (3 cohorts), sponsored by Beijing Jishuitan Hospital. Primary endpoints: Dose-Limiting Toxicities, Treatment-Emergent Adverse Events and Serious Adverse Events and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
mesenchymal stem cell exosomes
03
Conditions
osteonecrosis of the femoral head (ONFH)
Beyond the preview
Go deeper on NCT07787923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07787923.